Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of “Hold” by Brokerages

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have received a consensus rating of “Hold” from the fifteen brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $30.3333.

KROS has been the subject of a number of research analyst reports. Wells Fargo & Company reduced their target price on Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. Zacks Research raised Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, November 7th. Bank of America lifted their target price on Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a report on Friday, November 28th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a research report on Monday. Finally, Oppenheimer reiterated an “outperform” rating and issued a $27.00 price target (up previously from $23.00) on shares of Keros Therapeutics in a report on Wednesday, November 12th.

Keros Therapeutics Trading Down 2.0%

Shares of Keros Therapeutics stock opened at $16.83 on Wednesday. The firm’s 50 day simple moving average is $16.03 and its two-hundred day simple moving average is $15.01. The firm has a market capitalization of $512.81 million, a price-to-earnings ratio of 10.93, a PEG ratio of 0.22 and a beta of 0.89. Keros Therapeutics has a 12-month low of $9.12 and a 12-month high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.93. The business had revenue of $14.26 million during the quarter, compared to the consensus estimate of $4.22 million. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The business’s revenue for the quarter was up 3585.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.41) earnings per share. On average, sell-side analysts predict that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Insider Buying and Selling at Keros Therapeutics

In related news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $84,975,125.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the company’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $95,659,436.00. Additional details regarding this sale are available in the official SEC disclosure. 22.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Keros Therapeutics

A number of institutional investors have recently modified their holdings of the stock. ADAR1 Capital Management LLC grew its holdings in Keros Therapeutics by 6,294.5% in the first quarter. ADAR1 Capital Management LLC now owns 1,486,461 shares of the company’s stock valued at $15,147,000 after purchasing an additional 1,463,215 shares during the period. Western Standard LLC grew its stake in Keros Therapeutics by 42.7% in the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock valued at $34,644,000 after acquiring an additional 654,989 shares during the period. Vanguard Group Inc. grew its stake in Keros Therapeutics by 31.1% in the 1st quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company’s stock valued at $26,151,000 after acquiring an additional 609,212 shares during the period. DRW Securities LLC purchased a new stake in Keros Therapeutics in the 1st quarter worth $4,737,000. Finally, Canada Pension Plan Investment Board acquired a new position in Keros Therapeutics during the second quarter worth $4,251,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.